Selected article for: "acute respiratory syndrome and lower inflammatory"
Author: Steinman, Jonathan Baruch; Lum, Fok Moon; Ho, Peggy Pui-Kay; Kaminski, Naftali; Steinman, Lawrence
Title: Reduced development of COVID-19 in children reveals molecular checkpoints gating pathogenesis illuminating potential therapeutics
  • Cord-id: eflyypev
  • Document date: 2020_10_6
    • ID: eflyypev
    Snippet: The reduced development of COVID-19 for children compared to adults provides some tantalizing clues on the pathogenesis and transmissibility of this pandemic virus. First, ACE2, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) receptor, is reduced in the respiratory tract in children. Second, coronavirus associated with common colds in children may offer some protection, due to cross-reactive humoral immunity and T cell immunity between common coronaviruses and SARS-CoV-2. Third,
    Document: The reduced development of COVID-19 for children compared to adults provides some tantalizing clues on the pathogenesis and transmissibility of this pandemic virus. First, ACE2, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) receptor, is reduced in the respiratory tract in children. Second, coronavirus associated with common colds in children may offer some protection, due to cross-reactive humoral immunity and T cell immunity between common coronaviruses and SARS-CoV-2. Third, T helper 2 immune responses are protective in children. Fourth, surprisingly, eosinophilia, associated with T helper 2, may be protective. Fifth, children generally produce lower levels of inflammatory cytokines. Finally, the influence of the downturn in the global economy, the impact of living in quarters among families who are the most at risk, and factors including the openings of some schools, are considered. Those most disadvantaged socioeconomically may suffer disproportionately with COVID-19.

    Search related documents:
    Co phrase search for related documents
    • activator signal transducer and adaptive immunity: 1, 2
    • activator signal transducer and lung disease: 1, 2, 3, 4, 5
    • activator signal transducer and lung tissue: 1, 2, 3
    • active infection and acute respiratory distress syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
    • active infection and adaptive immunity: 1, 2, 3
    • active infection and additional study: 1
    • active infection and long term sequelae: 1
    • active infection and low concentration: 1
    • active infection and low respiratory: 1, 2, 3, 4
    • active infection and low respiratory tract: 1
    • active infection and lung barrier: 1
    • active infection and lung disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • active infection and lung immune response: 1
    • active infection and lung parenchyma: 1, 2
    • active infection and lung tissue: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • active infection and lung viral infection: 1, 2, 3